Peter Kurniali is an Oncology physician. OpenAlex indexes 26 publications with 460 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 N 7th St
Bismarck, ND 585014439
Telephone
701-323-6000Provider last certified this registry record 25 Mar 2022.
Industry payments
68 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20254 payments
- ABBVIE INC.Program year202510 payments
- PFIZER INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.9%Thalidomide Analog8.2%Revlimid68%Pomalyst32%Part D<11 patientsAromatase Inhibitor7.3%Letrozole50%Anastrozole50%Part D≥14 patients+ 7 more classes in this area
Metabolism & gastrointestinal
18.1%Corticosteroid11.2%Prednisone100%Part D≥50 patientsSerotonin-3 Receptor Antagonist4.5%Ondansetron Odt71%Ondansetron Hcl29%Part D≥41 patients+ 2 more classes in this area
Blood & clotting
15.2%Factor Xa inhibitor14%Eliquis77%Xarelto23%Part D<11 patientsLow Molecular Weight Heparin1.2%Enoxaparin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-world Utilization of Tissue-free Circulating Tumor DNA (ctDNA) Monitoring Across Tumor and Therapy Types
The Journal of Liquid Biopsy
2025 - Utilization of Circulating Tumor Cells in the Management of Solid Tumors
Journal of Personalized Medicine
2023 - Opioid use prior to admission for chemotherapy induced febrile neutropenia is associated with increased documented infection, sepsis, and death
Journal of Infection and Chemotherapy
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”